AZ

AZN

NYSE

AstraZeneca PLC

Healthcare
Drug Manufacturers - General
United Kingdom
179.54USD
-2.73 (-1.50%)
Market Cap: 282.68B USD

Revenue and Net Income

Values in USD

Income Statement

Values in USD

Financial itemTTMSep 30, 2026Dec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022
Total Revenue
62.38B58.74B54.07B45.81B44.35B
Cost of Revenue
11.27B10.63B10.21B8.27B12.39B
Gross Profit
51.12B48.11B43.87B37.54B31.96B
Operating Expense
36.86B34.78B33.62B28.82B27.45B
Operating Income
14.26B13.33B10.25B8.72B4.51B
Net Non Operating Interest Income Expense
-1.35B-1.25B-1.34B-1.29B-1.25B
Pretax Income
13.30B12.40B8.69B6.90B2.50B
Tax Provision
2.27B2.17B1.65B938.00M-792.00M
Net Income Common Stockholders
11.03B10.22B7.04B5.96B3.29B
Diluted NI Available to Com Stockholders
11.03B10.22B7.04B5.96B3.29B
Basic EPS
7.126.604.543.842.12
Diluted EPS
7.066.544.503.812.11
Basic Average Shares
1.55B1.55B1.55B1.55B1.55B
Diluted Average Shares
1.56B1.56B1.56B1.56B1.56B
Total Operating Income as Reported
14.78B13.74B10.00B8.19B3.76B
Rent Expense Supplemental
—452.00M377.00M301.00M268.00M
Total Expenses
48.13B45.41B43.82B37.09B39.84B
Net Income from Continuing & Discontinued Operation
11.03B10.22B7.04B5.96B3.29B
Normalized Income
10.64B9.92B7.16B6.38B3.89B
Interest Income
352.00M360.00M345.00M301.00M81.00M
Interest Expense
1.71B1.61B1.68B1.59B1.33B
Net Interest Income
-1.35B-1.25B-1.34B-1.29B-1.25B
EBIT
15.01B14.02B10.37B8.49B3.83B
EBITDA
21.17B19.51B15.44B13.42B9.09B
Reconciled Cost of Revenue
11.27B10.63B10.21B8.27B12.39B
Reconciled Depreciation
6.17B5.49B5.07B4.93B5.25B
Net Income from Continuing Operation Net Minority Interest
11.03B10.22B7.04B5.96B3.29B
Total Unusual Items Excluding Goodwill
467.00M367.00M-153.00M-489.00M-741.00M
Total Unusual Items
467.00M367.00M-153.00M-489.00M-741.00M
Normalized EBITDA
20.71B19.14B15.59B13.91B9.83B
Tax Rate for Calcs
0.170.170.190.140.19
Tax Effect of Unusual Items
79.57M64.19M-29.05M-66.49M-140.79M

Key Statistics

Valuation

Market Cap (USD)282.68B
Market Cap (Local)282.68B
P/E (TTM)25.63
P/S (TTM)4.53
MC/EBITDA13.35

Volume & Shares

Last Volume2.37M
Avg Vol (10D)1.93M
Avg Vol (30D)3.07M
Avg Vol (90D)3.47M
Shares Outstanding1.55B

Growth Indicators

Revenue TTM/Ann1.06
Net Income TTM/Ann1.08
EBITDA TTM/Ann1.09
Gross Profit TTM/Ann1.06
Operating Inc TTM/Ann1.07

Currency & Exchange

Trading CurrencyUSD
Financial CurrencyUSD
Trading/USD Rate1.00
Financial/USD Rate1.00
ExchangeNYSE

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.